Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Annovis Bio (ANVS)
NYSE:ANVS
Annovis Bio (ANVS) Stock Price & Analysis
509 Followers
ANVS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.53 - $22.49
Previous Close$11.33
Volume299.40K
Average Volume (3M)2.09M
Market Cap
$118.75M
Enterprise Value$123.47M
Total Cash (Recent Filing)$3.10M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Aug 05, 2024EPS Estimate
-$0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.13
Shares Outstanding11,171,480
10 Day Avg. Volume220,236
30 Day Avg. Volume2,092,197
Standard Deviation0.40
R-Squared0.06
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)9.97
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.51
Forecast
1Y Price Target
$41.00Price Target Upside285.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Annovis Bio News
PremiumCompany Announcements
Annovis Bio Gains FDA Nod for Buntanetap Crystal Form
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyBuntanetap is safe and effective in improving motor and non-motor activities and improving cognitive functions in patients with early Parkinson’s disease.
Management ExpansionAnnovis Bio indicated earlier this month that it had expanded its executive management team with four additional appointments.
Regulatory ApprovalThe FDA has cleared the continuation of buntanetap's development using the new crystal form.
Bears Say
Financial UncertaintyThe company needs additional capital before the end of the year, and while seeking partnership opportunities, it will take time and is far from guaranteed.
Operational FundingExpect the company's resources to be sufficient only to fund operations for a couple of months; accordingly, anticipate further equity dilution near-term.
Trial ResultsThe total trial missed the primary endpoint, highlighting the need for a longer study to determine true effects.
---
Ownership Overview
26.28% Insiders
4.18% Mutual Funds
3.32% Other Institutional Investors
66.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANVS FAQ
What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was $4.53 and its highest was $22.49 in the past 12 months.
What is Annovis Bio’s market cap?
Currently, no data Available
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s upcoming earnings report date is Aug 05, 2024 which is in 14 days.
How were Annovis Bio’s earnings last quarter?
Currently, no data Available
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate is -$0.55.
How many shares outstanding does Annovis Bio have?
Annovis Bio has 11,171,480 shares outstanding.
What happened to Annovis Bio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in ANVS
---
Annovis Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.00 (285.70% Upside)
$41.00 (285.70% Upside)
Blogger Sentiment
Bullish
ANVS Sentiment 92%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 14.9%
Last 30 Days ▲ 14.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.17%
12-Months-Change
Fundamentals
Return on Equity
-566.49%
Trailing 12-Months
Asset Growth
-69.42%
Trailing 12-Months
Company Description
Annovis Bio
Annovis Bio Inc is a United States based clinical stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neuro degenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.
---
ANVS Stock 12 Month Forecast
Average Price Target
$41.00
▲(285.70% Upside)
Technical Analysis
Apellis Pharmaceuticals
―
Anavex Life Sciences
―
Cytokinetics
―
Voyager Therapeutics
―
Best Analysts Covering ANVS
1 Year
1 Year Success Rate
6/17 ratings generated profit
1 Year Average Return
-0.86%
reiterated a buy rating 6 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of -0.86% per trade.
---